
A consistent
from patients:
Is "worth it" to travel to a specialty cancer to receive #cancer treatment?
A consistent
from health economics professionals:
How can PPS exempt cancer centers justify charging higher prices?
https://jamanetwork.com/journals/jamaoncology/fullarticle/2451426

Is "worth it" to travel to a specialty cancer to receive #cancer treatment?
A consistent

How can PPS exempt cancer centers justify charging higher prices?
https://jamanetwork.com/journals/jamaoncology/fullarticle/2451426
Overall the data can be mixed. The 2015 study showed a measurable survival increase from community
academic
NCI
PPS exempt. A 2019 @JAMAInternalMed study showed no differences in mortality for surgical candidates compared to NCI centers. https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2735987



There is specific #financialtoxicity related to specialty cancer care. Less than half of #ACA plans had "in-network" access to an NCI cancer center. The travel burden for gas, hotels, PARKING, for some patients is insurmountable. https://ascopubs.org/doi/10.1200/JCO.2016.69.9835?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
I often wonder if cancer outcome might frankly be driven MORE by the type of insurance you have and the uncaptured socioeconomic differences that brought you to seek care at a specialty cancer center than the "improved" cancer care that you receive here. https://journals.lww.com/amjclinicaloncology/Fulltext/2008/04000/Impact_of_Treatment_and_Socioeconomic_Status_on.3.aspx
These are the
s that keep me up at night as I consider my role in both trying prevent #financialtoxicity and potentially contributing TO financial toxicity for my patients.

